Cardiovascular Disease in Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 303

[20] Weis SM, Emery JL, Becker KD, McBride Jr DJ, Omens JH,

McCulloch AD. Myocardial mechanics and collagen struc-
ture in the osteogenesis imperfecta murine (oim). Circ Res
2000;87(8):663-9.

for transforming growth factor-β on osteoblasts from patients
with osteogenesis imperfecta. Pathobiology 2000;68(3):106-12.
[35] Strauss CE, Duval S, Pastorius D, Harris KM. Pharmacotherapy
in the treatment of mitral regurgitation: a systematic review.
J Heart Valve Dis 2012;21(3):275-85.
[36] Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibi-
tors for pulmonary arterial hypertension. N Engl J Med 2009;
361(19):1864-71.
[37] Vaishnava P, Fuster V, Goldman M, Bonow RO. Surgery for
asymptomatic degenerative aortic and mitral valve disease. Nat
Rev Cardiol 2011;8(3):173-7.
[38] Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF,
Casey Jr DE, et al. ACCF/AHA/AATS/ACR/ASA/SCA/
SCAI/SIR/STS/SVM Guidelines for the diagnosis and manage-
ment of patients with thoracic aortic disease. J Am Col Cardiol
2010;55(14):e27-129.
[39] Zegdi R, D'Attellis N, Fornes P, Fuzellier JF, Carteaux JP, Fabiani
JN, et al. Aortic valve surgery in osteogenesis imperfecta: report
of two cases and review of the literature. J Heart Valve Dis
1998;7(5):510-4.
[40] Wood SJ, Thomas J, Braimbridge MV. Mitral valve disease and
open heart surgery in osteogenesis imperfecta tarda. Br Heart J
1973;35(1):103-6.
[41] Ohteki H, Ohtsubo S, Sakurai J, Koga N, Kohchi K, Itoh T.
Aortic regurgitation and aneurysm of Sinus of Valsalva asso-
ciated with osteogenesis imperfecta. Thorac Cardiovasc Surg
1991;39(5):294-5.
[42] Chrysant GS, Cassivi SD, Carey CF, Sundt TM. Double valve
replacement in a patient with osteogenesis imperfecta. J Heart
Valve Dis 2002;11(5):751-4.
[43] Hall RMO, Henning RD, Brown TCK, Cole WG. Anaesthesia for
children with osteogenesis imperfecta - a review covering 30
years and 266 anaesthetics. Pediatr Anesth 1992;2(2):115-21.
[44] Stynowick GA, Tobias JD. Perioperative care of the patient with
osteogenesis imperfecta. Orthopedics 2007;30(12):1043-9.
[45] Peluso A, Cerullo M. Malignant hyperthermia susceptibil-
ity in patients with osteogenesis imperfecta. Pediatr Anesth
1995;5(6):398-9.
[46] Rampton AJ, Kelly DA, Shanahan EC, Ingram GS. Occurrence
of malignant hyperpyrexia in a patient with osteogenesis imper-
fecta. Br J Anaesth 1984;56(12):1443-6.
[47] Bojanic K, Kivela JE, Gurrieri C, Deutsch E, Flick R, Sprung J, et al.
Perioperative course and intraoperative temperatures in patients
with osteogenesis imperfecta. Eur J Anaesthesiol 2011;28(5):370-5.
[48] Migliaccio S, Barbero G, Fornari R, Di Lorenzo G, Celli M,
Lubrano C, et al. Impairment of diastolic function in adult
patients affected by osteogenesis imperfecta clinically asymp-
tomatic for cardiac disease: casuality or causality? Int J Cardiol
2009;131(2):200-3.

[21] McCormick RJ, Musch TI, Bergman BC, Thomas DP. Regional

differences in LV collagen accumulation and mature cross-
linking after myocardial infarction in rats. Am J Physiol 1994;
266(1):H354-9.

[22] Hofmann U, Bonz A, Frantz S, Hu K, Waller C, Roemer K, et al.

A collagen alpha2(I) mutation impairs healing after experimen-
tal myocardial infarction. Am J Pathol 2012;180(1):113-22.

[23] Liu X, Wu H, Byrne M, Jeffrey J, Krane S, Jaenisch R. A targeted

mutation at the known collagenase cleavage site in mouse type I
collagen impairs tissue remodeling. J Cell Biol 1995;130(1):227-37.

[24] Nong Z, O'Neil C, Lei M, Gros R, Watson A, Rizkalla A, et al.

Type I collagen cleavage is essential for effective ibrotic repair
after myocardial infarction. Am J Pathol 2011;179(5):2189-98.

[25] McAllion SJ, Paterson CR. Causes of death in osteogenesis

imperfecta. J Clin Pathol 1996;49(8):627-30.

[26] Thiele F, Cohrs CM, Flor A, Lisse TS, Przemeck GK, Horsch M,

et al. Cardiopulmonary dysfunction in the osteogenesis imperfecta
mouse model Aga2 and human patients are caused by bone-inde-
pendent mechanisms. Hum Mol Genet 2012;21(16):3535-45.

[27] Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK,

et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a
mouse model of Marfan syndrome. Science 2006;312(5770):117-21.

[28] Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y,

van Erp C, et al. Noncanonical TGFbeta signaling contributes to
aortic aneurysm progression in Marfan syndrome mice. Science
2011;332(6027):358-61.

[29] Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C,

Bedja D, et al. TGF-beta-dependent pathogenesis of mitral valve
prolapse in a mouse model of Marfan syndrome. J Clin Invest
2004;114(11):1586-92.

[30] Hirani R, Hanssen E, Gibson MA. LTBP-2 speciically interacts

with the amino-terminal region of ibrillin-1 and competes with
LTBP-1 for binding to this microibrillar protein. Matrix Biol
2007;26(4):213-23.

[31] Massam-Wu T, Chiu M, Choudhury R, Chaudhry SS, Baldwin AK,

McGovern A, et al. Assembly of ibrillin microibrils governs extra-
cellular deposition of latent TGFβ. J Cell Sci 2010;123(17):3006-18.

[32] Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B.

Differential effects of transforming growth factor-beta 1 and
phorbol myristate acetate on cardiac ibroblasts. Regulation of
ibrillar collagen mRNAs and expression of early transcription
factors. Circ Res 1991;69(2):483-90.

[33] Oganesian A, Au S, Horst JA, Holzhausen LC, Macy AJ, Pace

JM, et al. The NH2-terminal propeptide of type I procolla-
gen acts intracellularly to modulate cell function. J Biol Chem
2006;281(50):38507-18.

[34] Gebken J, Brenner R, Feydt A, Notbohm H, Brinckmann J,

Müller PK, et al. Increased cell surface expression of receptors